• Transcription factors (TFs) are master regulators of glioma stem cell (GSC) self-renewal, proliferation, differentiation, and transformation, driving glioblastoma (GBM) progression and recurrence.
• Targeting specific TFs offers a promising therapeutic strategy to disrupt multiple tumor attributes and overcome drug resistance in GBM.
• The review highlights the potential of TF inhibitors as novel clinical interventions, providing a foundation for developing new drug targets.
• Understanding TF-mediated regulation of GSCs may lead to improved diagnostic biomarkers and personalized treatment approaches for GBM.